Scientific article
French

Possibilités thérapeutiques actuelles des troubles anxieux généralisés

Published in

Revue médicale suisse, vol. 6, no. 255, p. 1370-1374

Publication date

2010

Abstract

Among a variety of drugs used in the treatment of anxiety disorders, benzodiazepines and antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are at present the most established and prescribed. In fact, recent guidelines recommend the antidepressants SSRI and SNRI as well as pregabaline, a newly developed drug, as the 1st choice treatment in generalized anxiety disorder (GAD). However, antidepressants have several disadvantages (latency of onset of action, adverse effects and drug interactions) that should not be neglected. Pregabaline is a drug with a new mechanism of action. Clinical studies up to now indicate a rather rapid and efficient anxiolytic effect comparable to that of benzodiazepines, with no risk of abuse. Pregabaline has been recently introduced in Switzerland for the treatment of GAD.

Keywords

  • Anti-Anxiety Agents/therapeutic use
  • Antidepressive Agents/therapeutic use
  • Anxiety Disorders/drug therapy
  • Humans

Citation (ISO format)

DELINI-STULA, Alexandra, BONDOLFI, Guido, HOLSBOER-TRACHSLER, Edith. Possibilités thérapeutiques actuelles des troubles anxieux généralisés. In: Revue médicale suisse, 2010, vol. 6, n° 255, p. 1370–1374.

Main files (1)

Article (Published version)

Identifiers

Additional URL for this publication

http://rms.medhyg.ch/numero-255-page-1370.htm

Journal ISSN

1660-9379
651views
2downloads

Technical informations

Creation

13/12/2013 10:41:00

First validation

13/12/2013 10:41:00

Update

14/03/2023 20:44:12

Status update

14/03/2023 20:44:12

Last indexation

30/10/2024 15:25:34
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated